Radiotherapy Devices Market Report 2025

This Radiotherapy Devices market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The radiotherapy devices market size has grown strongly in recent years. It will grow from $6.13 billion in 2024 to $6.71 billion in 2025 at a compound annual growth rate (CAGR) of 9.5%. The growth in the historic period can be attributed to growing incidence of cancer, patient-centric care, aging population, increasing awareness of radiotherapy devices, growing teletherapy and remote monitoring.

The radiotherapy devices market size is expected to see strong growth in the next few years. It will grow to $9.73 billion in 2029 at a compound annual growth rate (CAGR) of 9.7%. The growth in the forecast period can be attributed to proton therapy expansion, immunotherapy combination, remote monitoring and teletherapy, growing demand for precise and targeted radiation treatments, minimally invasive radiotherapy techniques. Major trends in the forecast period include proton therapy advancements, hypofractionated radiotherapy, adaptive radiotherapy, patient experience enhancement, artificial intelligence (ai) integration.

The rising prevalence of cancer is anticipated to drive the growth of the radiotherapy devices market in the future. Cancer prevalence refers to the total number or proportion of individuals within a population diagnosed with cancer at a specific point in time or over a defined period. Radiotherapy is frequently used as a primary or supportive treatment for newly diagnosed cancer patients. It is employed to shrink tumors, control cancer progression, or destroy cancer cells before or after surgical procedures. For example, in July 2024, the Australian Institute of Health and Welfare, an Australian government agency, reported that the number of cancer cases diagnosed in Australia increased from 160,570 in 2022 to 164,694 in 2023, marking a significant annual rise. This trend underscores the growing prevalence of cancer in the country. Consequently, the increasing prevalence of cancer is driving the demand for radiotherapy devices.

The growth of the radiotherapy devices market is further boosted by the increasing number of clinical trials. Clinical trials are research investigations designed to assess the safety, effectiveness, and potential benefits of various medical treatments, interventions, drugs, medical devices, diagnostic procedures, and healthcare strategies in human subjects. These trials play a pivotal role in evaluating the safety and effectiveness of new radiotherapy devices. They involve the application of these devices on actual patients to ensure precise and intended radiation delivery. For instance, as of May 2023, there are 452,604 registered clinical studies, with 64,838 actively seeking participants, according to information from Xtalks, a Canadian digital health company. Therefore, the surge in clinical trials is propelling the growth of the radiotherapy devices market.

The integration of Artificial Intelligence (AI) is a prominent trend in the radiotherapy devices market and is rapidly gaining recognition. The introduction of AI innovations in cancer care is anticipated to enhance the precision and speed of diagnosis, aid in clinical decision-making, and yield improved treatment outcomes. For example, in October 2022, HCG Cancer Hospital launched an AI-based radiation treatment technology for efficient radiotherapy. Conventional treatment planning procedures, which can take several days to generate an optimized radiation treatment plan, are being expedited by these new AI advancements. Furthermore, AI is expected to find applications in deep learning for treatment planning, clinical decision support, automated image-guided adaptive radiation therapy, and the mining of genomic and radiobiological data, all of which will contribute to the market's growth.

Major companies operating in the radiotherapy devices market are actively innovating new technologies such as The Versa HD to enhance their market profitability. The Versa HD is a linear accelerator system designed for radiation therapy. For instance, in May 2023, the Mitchell Cancer Institute introduced a new radiation technology known as The Versa HD. This system is capable of delivering Volumetric Modulated Arc Therapy (VMAT), which accelerates treatment delivery and enhances the patient's experience. The Versa HD also provides High-Definition Dynamic Radiosurgery (HDRS), equipped with special sequencing capabilities, effectively transforming the linear accelerator into a specialized solution for Stereotactic Radiosurgery (SRS).

In July 2022, BEBIG Medical GmbH, a German-based radiotherapy treatment organization, acquired Wolf-Medizintechnik GmbH, a medical technology manufacturing company also based in Germany, for an undisclosed sum. This acquisition has enabled BEBIG Medical to expand its range of X-ray therapy devices for treating joint conditions and superficial skin cancers. It is expected to strengthen BEBIG Medical's position in the brachytherapy equipment market, which encompasses X-ray treatment devices, while expanding its product offerings to better serve its clients.

Radiotherapy devices are utilized in cancer treatment by delivering high doses of radiation to eliminate cancer cells and reduce tumor size. These devices are designed to target and destroy cancerous cells while minimizing harm to the surrounding healthy tissues. Through techniques such as external beam radiation and brachytherapy, radiotherapy devices play an essential role in the treatment and management of cancer.

The primary product types of radiotherapy devices include external beam radiation therapy devices, linear accelerator devices (LINAC), and proton therapy devices. A medical linear accelerator, or LINAC, is a radiotherapy device typically employed for external beam radiation treatments in cancer patients. It delivers high-energy x-rays or electrons to the specific region of the patient's tumor. These devices find applications in treating various types of cancer, including skin cancer, breast cancer, prostate cancer, cervical cancer, lung cancer, and others. Radiotherapy devices are used in healthcare settings such as hospitals, ambulatory surgical centers, and oncological treatment centers.

The radiotherapy devices market research report is one of a series of new reports that provides radiotherapy devices market statistics, including radiotherapy devices industry global market size, regional shares, competitors with a radiotherapy devices market share, detailed radiotherapy devices market segments, market trends and opportunities, and any further data you may need to thrive in the radiotherapy devices industry. This radiotherapy devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Major companies operating in the radiotherapy devices market include Varian Medical Systems Inc., Elekta AB, Accuray Incorporated, Becton Dickinson and Company, IBA Ion Beam Applications SA, Koninklijke Philips N.V., Siemens Aktiengesellschaft, Eckert & Ziegler Bebig, IsoRay Inc., General Electric Healthcare, Vision RT Ltd., RaySearch Laboratories AB, Theragenics Corporation, Canon Medical Systems Corporation, AngioDynamics Inc., Mitsubishi Electric Corporation, Shinva Medical Instrument Company Limited, Neusoft Medical Systems Co. Ltd., Mevion Medical Systems Inc., Optivus Proton Therapy Inc., Panacea Medical Technologies Pvt. Ltd., P-Cure Ltd., Provision Healthcare LLC, Sumitomo Heavy Industries Ltd., ViewRay Inc., Miranda Medical, Nordion Inc., NTP Radioisotopes SOC Ltd., Curium, Hitachi Ltd., Brainlab AG, Best Theratronics Ltd., ProTom International Inc., RefleXion Medical Inc., Insightec Ltd., HistoSonics Inc., Novocure Ltd., TomoTherapy Incorporated, Agile MV LLC, CIVCO Radiotherapy, Neutron Therapeutics, Diapulse Corporation of America, Johari Digital Healthcare Ltd., Alpha Tau Medical Ltd.

North America was the largest region in the radiotherapy devices market in 2024. Asia-Pacific was the second-largest region in the global radiotherapy devices market report. The regions covered in the radiotherapy devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the radiotherapy devices market report are Australia, China, India, Indonesia, Japan, South Korea, Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, USA, Canada, Mexico, Brazil, Chile, Argentina, Colombia, Peru, France, Germany, UK, Austria, Belgium, Denmark, Finland, Ireland, Italy, Netherlands, Norway, Portugal, Spain, Sweden, Switzerland, Russia, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.

The radiotherapy devices market consists of sales of external beam radiation therapy devices, linear accelerator devices, and proton therapy devices that are used for radiotherapy. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.